GlassScriptPhysician profile
Jenny Z Lin
NPI 1659361616
$10,374.31
in general payments reported to CMS, 2019-2025
47 companies · $560 in 2025
The $560 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,886 · 2020: $1,287 · 2021: $1,336 · 2022: $1,734 · 2023: $1,403 · 2024: $2,169 · 2025: $560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,131.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $1,304.76 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $1,157.69 | 2019-2025 | |
| Ucb, INC. | $967.37 | 2019-2025 | Briviact, Nayzilam |
| Biogen, INC. | $808.10 | 2019-2024 | Vumerity, Spinraza |
| Gilead Sciences, INC. | $747.71 | 2019-2024 | Vemlidy, Livdelzi |
| Sumitomo Pharma America, INC. | $745.35 | 2023-2024 | Aptiom |
| Eisai INC. | $713.19 | 2019-2025 | |
| Neurelis, INC. | $527.94 | 2020-2025 | Valtoco |
| Genentech USA, INC. | $226.00 | 2019-2025 | Ocrevus Zunovo |
| Abbvie INC. | $218.09 | 2021-2024 | |
| Neurocrine Biosciences, INC. | $215.96 | 2019-2025 | Ingrezza, Ongentys |
| Celgene Corporation | $202.42 | 2021-2023 | Zeposia |
| Amgen INC. | $182.03 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $149.50 | 2019-2023 | Nuplazid |
| Lilly USA, LLC | $146.12 | 2019-2023 | Amyvid |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $138.37 | 2024 | Freestyle Libre 3 |
| Dexcom, INC. | $134.89 | 2023 | Dexcom G7 Gss (161) |
| Penumbra, INC. | $129.31 | 2019 | |
| Phathom Pharmaceuticals, INC. | $125.00 | 2024 | Voquezna |
| Noven Pharmaceuticals, INC. | $124.99 | 2024 | Xelstrym |
| Genzyme Corporation | $114.99 | 2019-2022 | |
| Catalyst Pharmaceuticals, INC. | $104.12 | 2023-2024 | Fycompa |
| Teva Pharmaceuticals USA, INC. | $90.98 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $89.79 | 2019-2022 | |
| Emd Serono, INC. | $79.38 | 2019-2022 | |
| Vertos Medical, INC. | $77.74 | 2019 | |
| Avion Pharmaceuticals | $73.04 | 2022-2023 | Dhivy |
| Insightec,INC | $67.01 | 2025 | Exablate |
| Allergan, INC. | $63.07 | 2020 | |
| Novo Nordisk INC | $62.34 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $60.33 | 2021 | |
| Ani Pharmaceuticals, INC. | $58.93 | 2023 | Purified Cortrophin Gel |
| Lundbeck LLC | $56.62 | 2025 | Vyepti |
| Adamas Pharmaceuticals, INC. | $50.04 | 2021 | |
| Amneal Pharmaceuticals LLC | $44.43 | 2024 | Rytary, Ongentys |
| Corium, LLC | $39.40 | 2023 | Adlarity |
| Vertical Pharmaceuticals, LLC | $35.48 | 2019-2020 | |
| Ge Healthcare | $34.76 | 2019 | |
| Janssen Pharmaceuticals, INC | $28.72 | 2020 | |
| Sk Life Science, INC. | $28.13 | 2024 | |
| Aucta Pharmaceuticals, INC. | $27.23 | 2025 | Motpoly Xr |
| Banner Life Sciences, LLC | $24.41 | 2022 | |
| Livanova USA, INC. | $24.29 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Medtronic USA, INC. | $22.37 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $18.66 | 2020 | |
| Grifols USA, LLC | $17.87 | 2021 | |
| Merck Sharp & Dohme LLC | $15.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenny Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.